- Home
- BRNS vs STTK Comparison
BRNS vs STTK Comparison
Compare BRNS & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRNS
- STTK
- Stock Information
- Founded
- BRNS 2016
- STTK 2016
- Country
- BRNS United Kingdom
- STTK United States
- Employees
- BRNS N/A
- STTK N/A
- Industry
- BRNS Biotechnology: Pharmaceutical Preparations
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- BRNS Health Care
- STTK Health Care
- Exchange
- BRNS Nasdaq
- STTK Nasdaq
- Market Cap
- BRNS 48.3M
- STTK 49.3M
- IPO Year
- BRNS 2021
- STTK 2020
- Fundamental
- Price
- BRNS $1.17
- STTK $0.95
- Analyst Decision
- BRNS Strong Buy
- STTK Hold
- Analyst Count
- BRNS 1
- STTK 5
- Target Price
- BRNS $3.00
- STTK $2.00
- AVG Volume (30 Days)
- BRNS 53.0K
- STTK 5.3M
- Earning Date
- BRNS 08-07-2025
- STTK 08-14-2025
- Dividend Yield
- BRNS N/A
- STTK N/A
- EPS Growth
- BRNS N/A
- STTK N/A
- EPS
- BRNS N/A
- STTK N/A
- Revenue
- BRNS $14,969,000.00
- STTK $2,997,000.00
- Revenue This Year
- BRNS N/A
- STTK N/A
- Revenue Next Year
- BRNS N/A
- STTK N/A
- P/E Ratio
- BRNS N/A
- STTK N/A
- Revenue Growth
- BRNS 1766.46
- STTK N/A
- 52 Week Low
- BRNS $0.64
- STTK $0.69
- 52 Week High
- BRNS $2.92
- STTK $3.95
- Technical
- Relative Strength Index (RSI)
- BRNS 48.60
- STTK 56.29
- Support Level
- BRNS $1.10
- STTK $0.79
- Resistance Level
- BRNS $1.23
- STTK $1.07
- Average True Range (ATR)
- BRNS 0.13
- STTK 0.10
- MACD
- BRNS -0.02
- STTK 0.02
- Stochastic Oscillator
- BRNS 46.15
- STTK 71.34
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.